• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intrinsic molecular subtypes of HER2+ breast cancer.

作者信息

Prat Aleix, Pascual Tomás, Adamo Barbara

机构信息

Aleix Prat: Department of Medical Oncology, Hospital Clínic de Barcelona, Spain and Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.

出版信息

Oncotarget. 2017 Sep 4;8(43):73362-73363. doi: 10.18632/oncotarget.20629. eCollection 2017 Sep 26.

DOI:10.18632/oncotarget.20629
PMID:29088709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5650264/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb1a/5650264/3304366d9f49/oncotarget-08-73362-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb1a/5650264/3304366d9f49/oncotarget-08-73362-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb1a/5650264/3304366d9f49/oncotarget-08-73362-g001.jpg

相似文献

1
Intrinsic molecular subtypes of HER2+ breast cancer.HER2阳性乳腺癌的内在分子亚型
Oncotarget. 2017 Sep 4;8(43):73362-73363. doi: 10.18632/oncotarget.20629. eCollection 2017 Sep 26.
2
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.曲妥珠单抗和拉帕替尼联合化疗治疗早期 HER2 阳性乳腺癌的病理完全缓解预测因子（PAMELA）：一项开放标签、单组、多中心、Ⅱ期临床试验
Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24.
3
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.来曲唑联合或不联合拉帕替尼治疗激素受体阳性转移性乳腺癌的内在亚型的预后价值。
JAMA Oncol. 2016 Oct 1;2(10):1287-1294. doi: 10.1001/jamaoncol.2016.0922.
4
Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.HER2阳性乳腺癌内在亚型的分子特征与生存结局
J Natl Cancer Inst. 2014 Aug 19;106(8). doi: 10.1093/jnci/dju152. Print 2014 Aug.
5
Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.受体表达的综合分析反映了 HR+/HER2+乳腺癌的肿瘤内和肿瘤间异质性。
Breast Cancer Res Treat. 2022 Jul;194(2):221-230. doi: 10.1007/s10549-022-06629-w. Epub 2022 Jun 14.
6
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.解读HER2阳性乳腺癌：生物学及临床意义
Front Oncol. 2019 Oct 29;9:1124. doi: 10.3389/fonc.2019.01124. eCollection 2019.
7
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.HER2阳性乳腺癌新辅助曲妥珠单抗化疗后基线及残留肿瘤中的PAM50亚型：来自单一机构的连续病例系列
Front Oncol. 2019 Aug 6;9:707. doi: 10.3389/fonc.2019.00707. eCollection 2019.
8
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.依维莫司联合依西美坦治疗激素受体阳性晚期乳腺癌：BOLERO-2 研究的 PAM50 内在亚型分析。
Oncologist. 2019 Jul;24(7):893-900. doi: 10.1634/theoncologist.2018-0407. Epub 2019 Jan 24.
9
Clinical implications of the intrinsic molecular subtypes of breast cancer.乳腺癌内在分子亚型的临床意义。
Breast. 2015 Nov;24 Suppl 2:S26-35. doi: 10.1016/j.breast.2015.07.008. Epub 2015 Aug 5.
10
Prediction consistency and clinical presentations of breast cancer molecular subtypes for Han Chinese population.汉族人群乳腺癌分子亚型的预测一致性及临床特征。
J Transl Med. 2012 Sep 19;10 Suppl 1(Suppl 1):S10. doi: 10.1186/1479-5876-10-S1-S10.

引用本文的文献

1
Differences in the distribution of HER2-positive breast tumors according to ethnicity and genetic variants in : a special focus on Asian and Latina women.根据种族和基因变异的HER2阳性乳腺肿瘤分布差异：特别关注亚洲和拉丁裔女性。
Front Oncol. 2025 Jul 24;15:1635681. doi: 10.3389/fonc.2025.1635681. eCollection 2025.
2
Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar.HER2 阳性晚期乳腺癌的新兴治疗方法：不断提高标准。
Cell Rep Med. 2024 Jun 18;5(6):101575. doi: 10.1016/j.xcrm.2024.101575. Epub 2024 May 16.
3
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls.

本文引用的文献

1
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.曲妥珠单抗和拉帕替尼联合化疗治疗早期 HER2 阳性乳腺癌的病理完全缓解预测因子（PAMELA）：一项开放标签、单组、多中心、Ⅱ期临床试验
Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24.
2
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.切洛布试验中化疗和曲妥珠单抗治疗的 HER2 阳性乳腺癌患者的 PAM50 亚型综合评估和免疫调节。
Ann Oncol. 2016 Oct;27(10):1867-73. doi: 10.1093/annonc/mdw262. Epub 2016 Aug 2.
3
乳腺癌中HER2的缺失：生物学机制与技术陷阱
Cancer Drug Resist. 2022 Oct 20;5(4):971-980. doi: 10.20517/cdr.2022.55. eCollection 2022.
4
Association of genetic ancestry with HER2, GRB7 AND estrogen receptor expression among Colombian women with breast cancer.哥伦比亚乳腺癌女性中遗传血统与HER2、GRB7及雌激素受体表达的关联
Front Oncol. 2022 Dec 22;12:989761. doi: 10.3389/fonc.2022.989761. eCollection 2022.
5
Transcription profiling of feline mammary carcinomas and derived cell lines reveals biomarkers and drug targets associated with metabolic and cell cycle pathways.猫乳腺肿瘤及其衍生细胞系的转录谱分析揭示了与代谢和细胞周期途径相关的生物标志物和药物靶点。
Sci Rep. 2022 Oct 11;12(1):17025. doi: 10.1038/s41598-022-20874-5.
6
Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2.三靶点联合治疗激素受体阳性、HER2 过表达型乳腺癌
Mol Cancer Ther. 2022 Jan;21(1):48-57. doi: 10.1158/1535-7163.MCT-21-0098. Epub 2021 Nov 2.
7
A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.一种 HER2 靶向抗体药物偶联物联合抗 PD-(L)1 治疗可消除 hPD-1 转基因小鼠模型中的 hHER2+肿瘤，并有助于形成免疫记忆。
Breast Cancer Res Treat. 2022 Jan;191(1):51-61. doi: 10.1007/s10549-021-06384-4. Epub 2021 Oct 16.
8
Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment.对接受新辅助治疗的HER2阳性乳腺癌患者中HER2富集亚型预测病理完全缓解的Meta分析。
Front Oncol. 2021 Jul 23;11:632357. doi: 10.3389/fonc.2021.632357. eCollection 2021.
9
Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer.靶向HER2阳性乳腺癌中的mTOR和糖酵解
Cancers (Basel). 2021 Jun 11;13(12):2922. doi: 10.3390/cancers13122922.
10
HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase.HER2 异构体特异性地调控肿瘤内异质性，并在隐匿性肿瘤发生阶段预先决定乳腺癌的发展轨迹。
Mol Cancer Res. 2021 Oct;19(10):1699-1711. doi: 10.1158/1541-7786.MCR-21-0215. Epub 2021 Jun 15.
Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.基于研究的 PAM50 亚型预测器可识别出 NOAH 研究中 HER2 阳性乳腺癌的更高反应和改善的生存结果。
Clin Cancer Res. 2014 Jan 15;20(2):511-21. doi: 10.1158/1078-0432.CCR-13-0239.
4
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.多中心 II 期研究：曲妥珠单抗和拉帕替尼联合激素治疗且不联合化疗治疗人表皮生长因子受体 2 过表达乳腺癌患者：TBCRC 006。
J Clin Oncol. 2013 May 10;31(14):1726-31. doi: 10.1200/JCO.2012.44.8027. Epub 2013 Apr 8.
5
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。
Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
6
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.PD0332991，一种选择性细胞周期蛋白 D 激酶 4/6 抑制剂，在体外优先抑制腔面雌激素受体阳性人乳腺癌细胞系的增殖。
Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.